Unlike traditional vaccines that rely on inactivated pathogens or recombinant proteins, nucleic acid vaccines deliver DNA or RNA molecules encoding antigens to directly synthesize target proteins in host cells and activate precise immune responses.
This path has shown great potential in the COVID-19 pandemic - it took only 11 months from sequence design to approval for mRNA vaccines, setting a new record in the history of drug development. It not only verifies the rapid response advantage of nuc...
